DARA BioSciences, Inc. (DARA), formerly Point therapeutics, Inc. is a
development stage pharmaceutical company that acquires therapeutic molecules
and medical technologies from third parties, and advances their clinical
development for later sale to pharmaceutical and biotechnology companies.
DARA focuses on two drug development programs: KRN5500 for neuropathic pain
in cancer patients and DB959 for type 2 diabetes. On February 12, 2008,
Point and DARA BioSciences, Inc. completed their merger transaction, in
which DP Acquisition Corp. (a wholly owned subsidiary of Point) merged with
and into DARA BioSciences, Inc.